Jacqueline Shea
-
With FDA Decision Looming, Plymouth Meeting’s Inovio Cuts Workforce to Preserve Cash
Over the past year, Plymouth Meeting-based Inovio Pharmaceuticals has reduced its workforce by 16 percent to preserve cash as it…
-
Plymouth Meeting-based Inovio Delays FDA Approval Plans for Experimental DNA Drug
Plymouth Meeting-based Inovio is delaying plans to seek Food and Drug Administration approval for its experimental DNA medicine as a…
-
Plymouth Meeting-based Inovio Expects to Raise $36M Following “Transformational” 2023
Plymouth Meeting-based Inovio Pharmaceuticals is expecting to raise $36 million through a stock offering this week, writes John George for…
-
Plymouth Meeting’s Inovio on Track to Launch First DNA Medicine in U.S.
Plymouth Meeting-based Inovio Pharmaceuticals is on the right track to launch its first product which would also be the first…
-
Plymouth Meeting’s Inovio Shares Spike After Positive FDA Reception on Groundbreaking Treatment
Plymouth Meeting biotech company Inovio’s innovations are paying off. Amid positive feedback from the FDA on an experimental respiratory disease…
-
Inovio Pulls Development of Two Vaccines; Stock-Price Health Weakens in Response
Plymouth Meeting pharmaceutical company Inovio has discontinued development of two vaccines, based on evidence of their ineffectiveness. As a result,…
-
Plymouth Meeting-based Inovio Replaces CEO, Switches Focus from COVID-19 Vaccine to Developing Booster
Plymouth Meeting-based Inovio has replaced co-founder J. Joseph Kim as CEO and announced that it will shift its focus from…
Founding Partners
Advertisement
Affiliate Partners
Community Partners
